Department of Clinical Oncology, Nottingham University Hospitals, NHS Trust-City Campus, Hucknall Road, Nottingham, UK.
Pathol Oncol Res. 2010 Sep;16(3):361-70. doi: 10.1007/s12253-009-9230-5. Epub 2009 Dec 19.
The aims of this study were to examine the significance of CD3+ cells in patients with epithelial ovarian cancer and to determine their influence on the disease in relation to their location within tumours. A 157-core tissue-microarray constructed from primary ovarian cancer patients treated at Nottingham-University-Hospitals (2000-2007) was stained for the T-cell marker CD3. The number of CD3+ cells in direct contact with tumour cells was counted per tumour area. These were considered as "intra-tumoural T-cells (ITTC)". Cores were divided into CD3 'high' or 'low' density tumours. "Stromal T-cells (STC)" were assigned as 'positive' or 'negative'. The study population had a median follow-up time of 36-months (0-75). The number of ITTC counted in tumour cores ranged between 0 and 184/mm(2). 90-tumours-(57%) were found to be in the "low-density" rubric, while 56-(36%) were of a "high-density" T-cell population. STC were found in 118-cores-(75%)-compared to 22-cores-(14%)-negative cores. Higher number of ITTC correlated with lower-grade-(p = 0.045), tumour-type-(p = 0.034), and longer-median-survival-times (57-versus 37-months for high-and low-ITTC densities, respectively, p = 0.038). This relationship was reversed when tumours were infiltrated by CD3+ cells in the stroma, predicting worse-survival (Log-rank-test, p = 0.028). Combining ITTC with STC produced an interesting pattern where the ITTC-low/STC + ve had the worst prognosis (p = 0.003). Infiltration of ovarian cancer by T-cells can influence its prognosis depending on the location of these cells (intra-tumoural-versus-stromal). The former predicts improved survival, while the latter is probably contributing to tumour progression and, in turn, worse survival.
本研究旨在探讨上皮性卵巢癌患者 CD3+细胞的意义，并确定其在肿瘤内位置对疾病的影响。本研究使用 Nottingham-University-Hospitals（2000-2007 年）治疗的原发性卵巢癌患者的 157 芯组织微阵列进行 T 细胞标志物 CD3 染色。按肿瘤面积计算与肿瘤细胞直接接触的 CD3+细胞数。这些被认为是“肿瘤内 T 细胞（ITTC）”。将芯分为 CD3“高”或“低”密度肿瘤。“基质 T 细胞（STC）”被分配为“阳性”或“阴性”。研究人群的中位随访时间为 36 个月（0-75 个月）。肿瘤芯中计数的 ITTC 数量在 0 至 184/mm2 之间。90 个肿瘤（57%）被归类为“低密度”，而 56 个肿瘤（36%）为“高密度”T 细胞群体。118 个芯（75%）中有 STC，而 22 个芯（14%）为阴性芯。ITTC 数量较高与较低分级（p=0.045）、肿瘤类型（p=0.034）和较长的中位生存时间相关（高 ITTC 密度组为 57 个月，低 ITTC 密度组为 37 个月，p=0.038）。当肿瘤被 CD3+细胞浸润时，这种关系发生逆转，预测生存更差（对数秩检验，p=0.028）。将 ITTC 与 STC 结合产生了一个有趣的模式，其中 ITTC 低/STC+ve 的预后最差（p=0.003）。T 细胞浸润卵巢癌可根据这些细胞的位置（肿瘤内与基质）影响其预后。前者预测生存改善，而后者可能有助于肿瘤进展，进而导致生存更差。
